Grants and Contributions:
Title:
513415
Agreement Number:
513415
Agreement Value:
$5,407,235.00
Agreement Date:
Sep 1, 2020 - Mar 31, 2022
Description:
This project is to advance a lead therapeutic drug candidate through Phase II clinical trials to treat severe cases of COVID-19, specifically in the lungs, kidney and liver.
Organization:
Innovation, Science and Economic Development Canada
Location:
Toronto, Ontario, CA M4T2M5
Reference Number:
033-2020-2021-Q3-513415
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
101328227
Recipient Type:
For-profit organization
Amendment Date
Apr 4, 2023
Recipient's Operating Name:
Arch Biopartners Inc.
Recipient's Legal Name:
Arch Biopartners Inc.
Federal Riding Name:
Toronto--St. Paul's
Federal Riding Number:
35090
Program:
SIF Stream 1- R&D
Program Purpose:
-Encourage R&D that will accelerate technology transfer and commercialization of innovative products, processes and services;-Facilitate the growth and expansion of firms in Canada;-Attract and retain large scale investments to Canada; and-Advance industrial research, development and technology demonstration through collaboration between academia, non-profit organizations and the private sector.
NAICS Code:
541710
Amendments: